Biologics/Immunotherapy News

As biologics become more popular for a growing number of indications, practices need to figure out the most cost-effective ways to provide these treatments to their patients.

Vaccinations can be safe and effective during dupilumab treatment, according to the consensus of a panel published in Annals of Allergy, Asthma & Immunology.

SAN DIEGO — Breath profile clusters can predict positive response to anti-IL5 or anti-IL5R alpha asthma treatment 1 month after initiation, according to an abstract presented at the American Thoracic Society International Conference.

SAN DIEGO — The relative expressions of three genes associated with the airway predicted mepolizumab response among urban children with asthma, according to a study presented at the American Thoracic Society International Conference.

SAN DIEGO — Study participants tolerated an inhaled therapeutic that silences the expression of a receptor for advanced glycation end-products in the lungs, according to a poster at the American Thoracic Society International Conference.

SAN DIEGO — Rates of serious adverse events for patients on mepolizumab were comparable with those using placebo across 7,429 patient-years of exposure, according to a presentation at the American Thoracic Society International Conference.

SAN DIEGO — Patients with asthma experienced significant reductions in mucus airway plugging and mucus volume with dupilumab, according to a presentation at the American Thoracic Society International Conference.

SAN DIEGO — Patients with severe asthma often experience residual mucus plugging even with biologic treatment, according to a presentation at the American Thoracic Society International Conference.

The FDA has accepted for priority review the supplemental biologics license application of dupilumab for adolescents with chronic rhinosinusitis with nasal polyps, Regeneron Pharmaceuticals Inc. and Sanofi announced in a press release.

Patients treated with allergen immunotherapy for pollen used less nasal inhaler medication during their first 5 years of treatment than patients who did not use immunotherapy, according to a study published in Allergy.